EPID-25. HOW MANY PATIENTS IN A REAL WORLD GLIOBLASTOMA POPULATION MEET ELIGIBILITY CRITERIA IN CLINICAL TRIALS?

In population series of glioblastoma (GBM) the median survival is < 1 year. For patients eligible for combined oncological treatment (surgery, radiotherapy (RT) and temozolomide (TMZ)) the median survival raises to 15 months. These patients are younger, have higher performance status and less com...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Skaga, Erlend, Andrea Skretteberg, Marthe, Børge Johannesen, Tom, Brandal, Petter, Osland Vik-Mo, Einar, Helseth, Eirik, Arne Langmoen, Iver
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Epidemiology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847494/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.325
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars